It has also been shown that treatment with a neutralizing anti-IL-17A antibody can reduce the angiogenesis of the tumor as well as reduce the inflammatory response, thereby reducing the growth of lung cancer progression (24, 26). This evidence concerns the gene IL17A and lung carcinoma.